Table III.
Cardiorespiratory exercise testing and echocardiography results at first, second, and third years of evaluation
| Test | Group | First year Mean (SD) | Second year Mean (SD) | Third year Mean (SD) | F value | p-valuea |
|---|---|---|---|---|---|---|
| AT MET | CL-FD | 3.28 (0.63) | 3.10 (0.58) | 3.34 (0.66) | 0.638 | 0.553 |
| CV-FD | 4.60 (1.48) | 4.18 (1.38) | 3.95 (1.34) | 6.202 | 0.088 | |
| PEAK MET | CL-FD | 4.78 (1.22) | 4.72 (1.03) | 5.08 (0.97) | 4.73 | 0.640 |
| CV-FD | 6.55 (1.70) | 5.93 (1.50) | 5.43 (1.43)b | 21.279 | 0.002* | |
| Peak VO2 | CL-FD | 0.88 (0.30) | 0.85 (0.22) | 0.94 (0.26) | 0.595 | 0.574 |
| CV-FD | 1.55 (0.53) | 1.39 (0.48) | 1.26 (0.49) | 12.955 | 0.007* | |
| Peak power output, W | CL-FD | 59.40 (19.71) | 58.00 (17.56) | 63.40 (16.15) | 0.316 | 0.613 |
| CV-FD | 106.00 (45.13) | 89.00 (22.45) | 91.25 (30.90) | 0.424 | 0.673 | |
| Peak SBP | CL-FD | 134.40 (7.80) | 140.60 (23.66) | 147.20 (15.42) | 0.791 | 0.486 |
| CV-FD | 151.75 (17.80) | 153.25 (11.62) | 159.75 (33.18) | 0.312 | 0.743 | |
| Peak DBP | CL-FD | 74.20 (5.22) | 75.60 (4.10) | 79.00 (9.82) | 0.616 | 0.524 |
| CV-FD | 74.75 (2.06) | 74.25 (1.89) | 77.50 (13.18) | 0.253 | 0.652 | |
| Peak HR | CL-FD | 129.00 (15.17) | 109.4 (30.44) | 108.0 (29.91) | 1.674 | 0.247 |
| CV-FD | 118.50 (12.29) | 121.75 (21.61) | 113.75 (16.82) | 0.443 | 0.662 | |
| Peak RER | CL-FD | 1.02 (0.04) | 1.04 (0.04) | 1.10 (0.02)b | 9.416 | 0.008* |
| CV-FD | 1.11 (0.02) | 1.09 (0.03) | 1.10 (0.02) | 0.820 | 0.484 | |
| Peak HRR | CL-FD | 24.80 (14.41) | 18.6 (13.58) | 12.40 (14.60) | 2.559 | 0.138 |
| CV-FD | 25.75 (13.72) | 23.75 (11.56) | 18.75 (16.09) | 0.264 | 0.777 | |
| peakVO2% | CL-FD | 77.02 (14.45) | 77.98 (12.97) | 84.75 (5.02) | 1.040 | 0.397 |
| CV-FD | 85.97 (21.16) | 78.98 (18.83) | 73.51 (18.15)b | 16.547 | 0.004* | |
| IVS (mm) | CL-FD | 11.00 (2.00) | 10.80 (2.28) | 13.42 (4.85) | 3.202 | 0.137 |
| CV-FD | 13.00 (4.08) | 13.25 (3.95) | 13.73 (3.73) | 0.422 | 0.674 | |
| LVMI | CL-FD | 152.27 (51.59) | 139.14 (30.23) | 169.29 (64.11) | 1.394 | 0.302 |
| CV-FD | 169.42 (56.94) | 178.82 (72.97) | 178.41 (70.84) | 0.158 | 0.857 | |
| LVM (g) | CL-FD | 228.98 (84.76) | 205.15 (43.92) | 250.59 (96.11) | 1.581 | 0.264 |
| CV-FD | 294.16 (77.98) | 308.11 (104.61) | 305.35 (105.58) | 0.101 | 0.905 |
p < 0.05.
Within-group difference using repeated measures 1-way analysis of variance (ANOVA).
Post hoc analysis using Bonferroni test showed p-value <0.05 compared with first year.
CL-FD: classic Fabry disease; CV-FD: cardiac variant Fabry disease; AT: anaerobic threshold; MET: metabolic equivalent; AT MET: MET at the point of AT; peak MET: MET at peak exercise; peak VO2: peak oxygen consumption; peak HR: heart rate at peak exercise; peak RER: respiratory exchange ratio at peak exercise; HRR at 1 min: heart rate reserve at 1 min after termination of the test; peakVO2%: percentage of measured peak oxygen consumption to predicted value; IVS: interventricular septal thickness at end-diastole; LVMI: left ventricular mass index; LVM: mass of left ventricle; SD: standard deviation.